---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-071009"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:17:17.211316+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune sells TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds for $55M cash plus up to $30M milestones

## Summary
- Purchase price $55M cash at close; up to $30M in future regulatory/commercial milestone payments.
- US WorldMeds to offer employment to ~50% of workforce; Adaptimmune to reduce remaining staff by ~62%.
- Pre-tax restructuring costs of ~$7-8M in Q3 2025; CMO, CCO, CSO departing in August.
- Adaptimmune retains preclinical PRAME, CD70, allogeneic assets; restructures to support transition.
- Closing expected before August 4, 2025; financed by Oaktree and Athyrium debt.

## SEC filing metadata
- accession: 0001104659-25-071009
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000110465925071009/0001104659-25-071009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000110465925071009/tm2521829d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-071009
- JSON: https://secwatch.observer/filing/0001104659-25-071009.json
- Plain text: https://secwatch.observer/filing/0001104659-25-071009.txt

## Key facts
- Restructurings & Charges
  Adaptimmune Therapeutics PLC announced a restructuring with charges of approximately $7-8 million (approximately 62%).
  - Type: restructuring
  - Charge: approximately $7-8 million
  - Headcount: approximately 62%
  source text: On July 28, 2025, Adaptimmune announced a restructuring to support the continued development by US WorldMeds of TECELRA, lete-cel, afami-cel and uza-cel and to maximize value from the Company’s remaining assets, including its PRAME and CD-70 directed T-cell therapies (the “Restructuring”). Following the Transaction, the Company plans to further reduce its remaining workforce by approximately 62%. The planned reduction in workforce is subject to consultation with employee representatives in the United Kingdom regarding the plan. The Company anticipates that the majority of the reduction in workforce will be completed during the third quarter of 2025. As a result of these actions, the Company expects to incur pre-tax costs, relating to employee severance and other employee related costs, of approximately $7-8 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465925071009/0001104659-25-071009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.